Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
L Zubiaga-FernandezA Testera-MontesCarmen RondónN Perez-SanchezF Gomez-PerezJ M Vega-ChicoteJ BartraMarta FerrerIbon Eguiluz GraciaM J TorresPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2024)
Low blood basophil count and the presence of hypothyroidism might serve as biomarkers for the controller dose of OMA in severe CSU patients.